Navigation Links
Novartis Data Shows ACZ885 for Severe Gouty Arthritis Provided Better Pain Relief and Reduced Risk of New Attacks by Up to 68% vs. Steroid
Date:5/24/2011

acute gouty arthritis(1,2). Patients had suffered from three or more gouty arthritis attacks in the previous 12 months and were either unresponsive or intolerant to common therapies like NSAIDs or colchicine, or these treatments were contraindicated. Patients were randomized to receive a single dose of ACZ885 150 milligrams (mg) via subcutaneous (s.c.) injection or TA 40 mg via intramuscular (i.m.) injection(1,2). In the case of a new attack, patients received a new dose of the same treatment they were randomized to at baseline.

Both studies had the same two primary endpoints: pain intensity at 72 hours post-dose; and time to the first new gouty arthritis attack(1,2). Pain in the affected joint was measured according to an internationally recognized pain scale, the Visual Analog Scale (VAS).

In one study, patients treated with ACZ885 had significantly lower mean pain scores at 72 hrs, with pain intensity decreasing from 73.3 mm at baseline to 28.1 mm for ACZ885 vs. 74.8 mm at baseline to 39.5 mm for TA (p=0.0005)(1,16). Similarly, patients in the other study receiving ACZ885 had significantly lower mean pain scores at 72 hrs, with pain intensity decreasing from 74.9 mm at baseline to 22.1 mm for ACZ885 vs. 73.6 mm at baseline to 31.9 mm for TA (p=0.0018)(17).

The number of patients with new attacks across both studies was also significantly reduced with ACZ885 compared to TA(2). In the first study, nearly twice as many patients experienced a new gouty arthritis attack in the TA group compared to ACZ885 (40 vs. 21 patients respectively [p=0.0061])(18). In addition, in the second study nearly three times as many patients in the TA group experienced a new attack compared to ACZ885 (42 vs. 15 patients respectively [p=0.0001])(18). In the previous year, patients in both studies suffered an average of at least six attacks (6.5 for ACZ885 and seven for TA in study one; and 6.5 and 5.9 respectively in study two)(16,17).

ACZ885 was generally wel
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... Vycor Medical, Inc. ("Vycor" or the "Company") has ... quarter ended March 31, 2011, the year ended December ... June 30, 2010 and September 30, 2010 and the ... periodic reports filed with the Securities and Exchange Commission ...
... On Friday, August 19, veterinary cardiologists are going to ... Dog Heart Health Tour will stop with a soundproof ... Bark Park in Ridgefield, Conn. (Photo:   ... free heart health screenings, veterinarians will be available to ...
Cached Medicine Technology:Vycor Medical, Inc. Restatement of Financial Statements 2Vycor Medical, Inc. Restatement of Financial Statements 3Free Dog Heart Health Screenings Available August 19 in Connecticut 2
(Date:4/18/2014)... 2014) ― A new study in the American ... health-related Google searches reveals a recurring pattern that could ... , Investigators from San Diego State University, the Santa ... analyzed "healthy" Google searches (searches that included the term ... in the U.S. from 2005 to 2012. They found ...
(Date:4/17/2014)... have identified the first genetic variant specifically associated ... accounting for around 10-15 per cent of all ... of the breast cancer sub-type, called invasive lobular ... causes of this particular kind of breast cancer, ... research, published today (Thursday) in the journal ...
(Date:4/17/2014)... Diego School of Medicine report that older women, plucky ... loss are more likely to be compassionate toward strangers ... in this month,s issue of the International Journal ... associated with better health and well-being as we age, ... the outcomes of individuals whose deficits in compassion put ...
(Date:4/17/2014)... New Rochelle, NY, April 17, 2014U.S. military personnel ... "blast plus impact" concussive traumatic brain injury (TBI) ... were evacuated for other medical reasons. Differences in ... and depression 6-12 months after injury are reported ... , a peer-reviewed journal from Mary Ann Liebert, ...
(Date:4/17/2014)... 2014 By discovering a new mechanism that allows ... researchers at UC Irvine and the Salk Institute have ... or prevent stroke-induced brain damage. , A complex and ... death and primary reason for disability in the U.S. ... and lets blood-borne material into the brain, causing the ...
Breaking Medicine News(10 mins):Health News:New research shows people are thinking about their health early in the week 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:The ilk of human kindness 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2
... of Americans, WASHINGTON, Dec. 5 Many of ... treatment, HHS,Secretary Mike Leavitt said today in marking fulfillment ... community health centers., Health centers deliver primary and ... Charges for health care services at,health centers are set ...
... Dec. 5 One of the greatest fears ... Syndrome), but due to extreme,precautionary measures taken to ... are rising by surprising levels. After the introduction,of ... were reduced,significantly. However, during this same period, children ...
... more than 10 million Americans, Osteoarthritis of the knee ... disability among the elderly. While OA mainly affects ... age. A double-blind, placebo-controlled study published in the journal ... from the bark of the French maritime pine tree, ...
... For patients with dialysis-related anemia, the risk of death ... a period several monthsnot necessarily when they fluctuate over ... Journal of the American Society of Nephrology. , "Our ... mortality, beyond the absolute level of hemoglobin, may not ...
... Certification for Pharmacy Techs, 91% ... Support Standards in Every State, ... the,Pharmacy Technician Certification Board (PTCB) shows that Americans have,strong misperceptions ... in pharmacies. The poll results,released today at the American Society ...
... HILL, N.C., Dec. 5 As companies transform ... with the art of selling while maintaining a ... in facilitating the changeover,the manager/supervisor is one of ... In fact, call center leaders recommend reducing ...
Cached Medicine News:Health News:HHS Marks Expansion of 1200th Health Center, Meeting Key Bush Goal 2Health News:Infant Development Program from EASY Baby Takes On the Sixty-Percent Increase in Developmental Delays in Children 2Health News:Study shows pine bark naturally reduces osteoarthritis knee pain 2Health News:Study shows pine bark naturally reduces osteoarthritis knee pain 3Health News:Study questions impact of hemoglobin variations on mortality in dialysis patients 2Health News:Survey Shows Broad Support Among Americans for Pharmacy Technician Certification 2Health News:Managing the Service-to-Sales Cultural Transformation - Complimentary Excerpt Available from Best Practices 2
... Conduit TCP is a synthetic porous ceramic graft ... to the mineral phase that comprises 70% of ... provides a scaffold that allows the attachment of ... of vascular networks within granules as well as ...
... an osteoconductive matrix constructed of cross-linked ... with hydroxyapatite through a proprietary 360 ... bone marrow aspirate, Healos provides an ... proliferation and differentiation. The hydroxyapatite-coated collagen ...
Blunt Weitlaner Retractor....
Beckman-Weitlaner retractor, blunt, with hinged arms, 6 1/2"....
Medicine Products: